Cargando…
Randomized Phase II JANUS Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria
INTRODUCTION: Patients with IgA nephropathy (IgAN) and persistent proteinuria are at risk of progression to kidney failure. Atacicept is a novel B-cell–targeted immunomodulator, shown to reduce immunoglobulin levels in patients with autoimmune diseases. METHODS: JANUS (NCT02808429) was a phase II st...
Autores principales: | Barratt, Jonathan, Tumlin, James, Suzuki, Yusuke, Kao, Amy, Aydemir, Aida, Pudota, Kishore, Jin, Hulin, Gühring, Hans, Appel, Gerald |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366370/ https://www.ncbi.nlm.nih.gov/pubmed/35967104 http://dx.doi.org/10.1016/j.ekir.2022.05.017 |
Ejemplares similares
-
Bortezomib for Reduction of Proteinuria in IgA Nephropathy
por: Hartono, Choli, et al.
Publicado: (2018) -
Seasonal proteinuria changes in IgA nephropathy patients after proteinuria remission
por: Inagaki, Koji, et al.
Publicado: (2017) -
Optimal Proteinuria Target for Renoprotection in Patients with IgA Nephropathy
por: Nam, Ki Heon, et al.
Publicado: (2014) -
Tacrolimus decreases proteinuria in patients with refractory IgA nephropathy
por: Hu, Tingyang, et al.
Publicado: (2018) -
Hydroxychloroquine Reduces Proteinuria in Indian Patients With IgA Nephropathy
por: Bagchi, Soumita, et al.
Publicado: (2022)